Use of totalin in the preparation of a medicine for resisting infection of escherichia coli

Abstract

The application discloses application of total mycin in preparation of a medicine for resisting escherichia coli infection and belongs to the technical field of antibacterial medicines. The application provides application of total mycin in preparation of a medicine for resisting escherichia coli infection. Research results show that the bacteriostatic effect of total mycin in vitro is clear. The application has clear antibacterial effect and good application prospect, and provides a new medicine selection for prevention and treatment of pathogenic escherichia coli infection.

Description

Technical Field

[0001] This invention relates to the field of antibacterial drug technology, and more specifically to the use of thiamycin in the preparation of drugs against Escherichia coli infection. Background Technology

[0002] Escherichia coli ( Escherichia coli , E.coli Escherichia coli (E. coli) can be classified as pathogenic or non-pathogenic. Non-pathogenic E. coli are an important component of the normal intestinal flora, while pathogenic E. coli are important pathogens causing various infectious diseases in humans and animals. For example, avian pathogenic E. coli... Escherichia coli (APEC) mainly uses serotypes such as O78, which can lead to diseases such as air sacculitis, pericarditis, perihepatitis, and septicemia, resulting in decreased poultry production performance and economic losses; Enterotoxigenic Escherichia coli (Enterotoxigenic) Escherichia coli ETEC, such as K88) and urinary tract pathogenic Escherichia coli (Uropathogenic Escherichia coli) Escherichia coli UPEC strains, such as J96, caused diarrhea and urinary tract infections in animals, respectively; meanwhile, multidrug-resistant (MDR) Escherichia coli strains (such as...) E. coli The emergence of B2 has further exacerbated the difficulty of prevention and control.

[0003] Currently, antibacterial drugs used to treat pathogenic Escherichia coli infections mainly include β-lactams, aminoglycosides, tetracyclines, and sulfonamides. However, these drugs have generally developed varying degrees of resistance over long-term use, especially with a significant reduction in their antibacterial activity against multidrug-resistant strains. There is an urgent need to find antibiotic resources with new structures and activities that possess good antibacterial activity, particularly inhibiting multidrug-resistant pathogenic Escherichia coli.

[0004] Holomycin is a dithiopyrrolidone antibiotic, belonging to the broad-spectrum antibiotic class, and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative bacteria. Previous studies have shown that holomycin has in vitro antibacterial activity against *Escherichia coli* strain K12, and its mechanism of action may be related to interference with RNA synthesis and influence on metal homeostasis. However, there is a lack of research on the antibacterial effect of holomycin against human and animal pathogenic *Escherichia coli*, especially clinically isolated multidrug-resistant pathogenic *Escherichia coli*, and its minimum inhibitory concentration (MIC) data remains unclear.

[0005] Therefore, investigating the inhibitory effects of tramycin on pathogenic Escherichia coli in humans and animals, as well as multidrug-resistant pathogenic Escherichia coli, and determining its minimum inhibitory concentration on these strains, is of great significance for evaluating the application value of tramycin as a potential antibacterial candidate drug and enriching the drug resource library against multidrug-resistant Escherichia coli. Summary of the Invention

[0006] In view of this, the purpose of the present invention is to provide the use of thiamycin in the preparation of drugs for treating Escherichia coli infection, so as to overcome the shortcomings of the prior art.

[0007] To achieve the above objectives, the present invention adopts the following technical solution:

[0008] This invention seeks protection for the use of thiamphenicol in the preparation of drugs for treating Escherichia coli infections.

[0009] Furthermore, the aforementioned Escherichia coli is an avian pathogenic Escherichia coli, preferably Avian pathogenic. Escherichia coli O78 (APEC O78) strain.

[0010] Furthermore, the aforementioned Escherichia coli is an enterotoxigenic Escherichia coli, preferably Enterotoxigenic. Escherichia coli K88 (ETEC K88) strain.

[0011] Furthermore, the aforementioned Escherichia coli is a urinary tract pathogenic Escherichia coli, preferably uropathogenic. Escherichia coli J96 (UPEC J96) strain.

[0012] Furthermore, the aforementioned Escherichia coli is a multidrug-resistant Escherichia coli, preferably... Escherichia coli B2 ( E. coli B2 strain.

[0013] An anti-Escherichia coli infection drug, comprising tramycin and pharmaceutically acceptable excipients.

[0014] As can be seen from the above technical solution, compared with the prior art, the beneficial effects of the present invention are as follows: This invention provides the application of tramycin in the preparation of drugs against Escherichia coli infections. In vitro antibacterial experiments confirmed that tramycin is effective against avian pathogenic Escherichia coli APEC O78 strain, enterotoxigenic Escherichia coli ETEC K88 strain, urinary tract pathogenic Escherichia coli UPEC J96 strain, and multidrug-resistant Escherichia coli. E. coli All B2 strains showed inhibitory activity. The results indicate that pomycin has a clear in vitro antibacterial effect. This invention has been experimentally verified to be effective, providing a new drug option for the prevention and treatment of pathogenic Escherichia coli infections, demonstrating clear antibacterial activity and promising application prospects. Attached Figure Description

[0015] Figure 1 The MICs of thiamethoxam are defined as follows: A: strain O78; B: strain K88; C: strain J96; D: strain B2. Detailed Implementation

[0016] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0017] Example 1 1. Introduction Holomycin, discovered in 1961, is a secondary metabolite of dithiopyrrolidones and is a broad-spectrum antibiotic. This invention primarily investigates the inhibitory effects of holomycin on pathogenic Escherichia coli in humans and animals, as well as multidrug-resistant pathogenic Escherichia coli, and determines its minimum inhibitory concentration (MIC) on these strains.

[0018] 2 Materials and Methods 2.1 Materials Drugs: Holomycin (CAS: 488-04-0, purity ≥98%) was purchased from Shanghai Taoshu Biotechnology Co., Ltd., and Enrofloxacin (CAS: 93106-60-6) was purchased from Shanghai Yuanye Biotechnology Co., Ltd.

[0019] Strains: Avian pathogenic Escherichia coli Escherichia coli O78 (APEC O78) strain (accession number CVCC 1556), enterotoxigenic Escherichia coli Escherichia coli The K88 (ETECK88) strain (accession number CVCC 225) was purchased from the China Veterinary Microbial Culture Collection Center (CVCC). Escherichia coli ( E.coli ATCC 25922 (Standard strain) is preserved by the Shanxi Provincial Key Laboratory of Modernization of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Shanxi Agricultural University; Uropathogenic Escherichia coli. Escherichia coli J96 (UPEC J96) strain, multidrug-resistant Escherichia coli Escherichia coli B2 ( E. coli Strain B2 was donated by Professor Zhu Kui of the National Key Laboratory of Veterinary Public Health Safety, College of Veterinary Medicine, China Agricultural University. All of the above strains are existing technologies.

[0020] 2.2 Determination of the minimum inhibitory concentration of tracycline against Escherichia coli strains O78, K88, J96, and B2 using the microbroth dilution method Eight concentration gradients of thiabendazole were prepared by serial dilution with cationic MH broth (CAMHB broth) at 2-fold concentrations. *E. coli* was inoculated into CAMHB broth and incubated at 37°C until the logarithmic growth phase. The bacterial culture was then diluted with CAMHB broth to a final concentration of 1 × 10⁻⁶. 6 CFU / mL. Add 18 μL of drug solution and 18 μL of bacterial solution to a 384-well plate, mix well, seal with membrane, and incubate at 37°C for 20 h (three replicates per dose; final DMSO concentration 2%). OD is measured using a microplate reader. 600 The nm value was used as the minimum inhibitory concentration (MIC) corresponding to the lowest concentration at which no visible bacterial growth was observed. Blank control wells (bacteria + CAMHB broth), sterile control wells (CAMHB broth), and solvent control wells (bacteria + CAMHB broth + DMSO, with a final DMSO concentration of 2%) were also set up. Quality control was performed using the standard quality control strain ATCC 25922.

[0021] 3 Results The MICs of tramycin on Escherichia coli strains O78, K88, J96, and B2 are as follows: Figure 1 As shown in Table 1.

[0022] Table 1. MICs of tramycin on Escherichia coli strains O78, K88, J96, and B2.

[0023] Depend on Figure 1 As shown in Table 1, tramycin has an inhibitory effect on Escherichia coli strains O78, K88, J96 and B2. The MIC of tramycin against Escherichia coli strains O78, K88 and J96 is 0.53565 μg / mL (2.5 μmol / L), and the MIC of tramycin against Escherichia coli strain B2 is 2.1426 μg / mL (10 μmol / L).

[0024] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of thiamphenicol in the preparation of drugs for treating Escherichia coli infection.

2. The application according to claim 1, characterized in that, The Escherichia coli mentioned is a pathogenic avian Escherichia coli.

3. The application according to claim 2, characterized in that, The pathogenic Escherichia coli in birds is Avianpathogenic. Escherichia coli O78 strain.

4. The application according to claim 1, characterized in that, The Escherichia coli mentioned is an enterotoxin-producing Escherichia coli.

5. The application according to claim 4, characterized in that, The enterotoxigenic Escherichia coli is Enterotoxigenic Escherichia coli K88 strain.

6. The application according to claim 1, characterized in that, The Escherichia coli mentioned is a urinary tract pathogenic Escherichia coli.

7. The application according to claim 6, characterized in that, The urinary tract pathogenic Escherichia coli is Uropathogenic Escherichia coli J96 strain.

8. The application according to claim 1, characterized in that, The Escherichia coli in question is a multidrug-resistant Escherichia coli.

9. The application according to claim 8, characterized in that, The multidrug-resistant Escherichia coli is Escherichia coli B2 strain.

10. A drug for treating Escherichia coli infection, characterized in that, This includes pharmacomycin and pharmaceutically acceptable excipients.

Images